|
Included drugs (n)
|
Ipilimumab, Pembrolizumab, Nivolumab
|
Abiraterone acetate, Brentuximab vedotin, Bosutinib, Ziv-aflibercept, Dabrafenib, Afatinib, Belinostat, Ramucirumab, Blinatumomab, Olaparib
|
|
Drug approval characteristics, n (%)
|
Priority review 0, orphan drug 3 (100%), breakthrough therapy 2 (67%), accelerated approval 2 (67%)
|
Priority review 4 (40%), orphan drug 7 (70%), breakthrough therapy 1 (10%), accelerated approval 4 (40%)
|
| |
ICPi trials (n = 19)
|
Other anticancer drug trials (n = 101)
|
|
Study phase, n (%)
|
|
Phase 1
|
5 (26)
|
42 (42)
|
|
Phase 2
|
9 (47)
|
48 (48)
|
|
Phase 3
|
5 (26)
|
11 (11)
|
|
Efficacy study, n (%)
|
11 (58)
|
18 (18)
|
|
Randomized study, n (%)
|
12 (63)
|
28 (28)
|
|
Double-blinded study, n (%)
|
7 (37)
|
13 (13)
|
|
Multi-country study, n (%)
|
12 (63)
|
52 (51)
|
|
Author affiliation with industry, n (%)
|
18 (95)
|
82 (81)
|
|
Sample size, median (IQR)
|
284 (127–676)
|
58 (37–121)
|
|
Statistically significant outcomeª, n (%)
|
8 (42)
|
10 (10)
|
|
Reporting of adverse events, n (%)
|
19 (100)
|
91 (90)
|
|
Selective outcome reporting, n (%)
|
6 (32)
|
21 (21)
|
